BRIEF—Eisai targeting more than $7 billion peak sales for Leqembi by 2030

At a press conference last week, executives of Japanese drug major Eisai forecast $7 billion 1 trillion yen ($7.3 billion) forecast worldwide sales by 2030 for its recently US-approved Alzheimer’s treatment Leqembi (lecanemab), assuming broader coverage from the Centers for Medicare and Medicaid Services (CMS), which has so far limited the use of any amyloid-targeted Alzheimer’s drugs to clinical trials.

The 1 trillion yen projection is based on the company’s estimate that about 2.5 million people will be eligible for treatment by 2030, with prevalence in Asia/Latin America and China potentially reaching 70% of the global total.

Eisai said it thinks there will be a jump in lecanemab sales worldwide in 2025, with wider availability of new blood-based biomarker technology

The drug is partnered with US biotech Biogen.

See presentation at: https://www.eisai.com/ir/library/presentations/pdf/e4523_20230310.pdf